Rather than following restrictive diets or generic programs, medical weight loss targets the root causes that make weight management difficult, such as hormone disruptions, metabolism challenges, and underlying health factors
Retatrutide trials excluded pregnant and breastfeeding individuals
By combining physician-led protocols, customized formulations, and direct-to-door delivery, MEDVi removes logistical and cost barriers traditionally associated with advanced weight loss treatments
The Phase 3 TRIUMPH program is generating the data the FDA requires, and if the trials read out as expected, the retatrutide FDA approval story that began with a striking Phase 2 paper in 2023 will likely have its next chapter written in 2026
This is not talked about enough